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Introduction 
Chromatographic techniques have been developed and 
successfully applied for the analysis of a considerable of 
number of organic and inorganic compounds present at trace 
level in sometimes complicated accompanying matrices. 
The rapid development of new chromatographic 
instrumentation and separation strategies resulted in the 
increase of the number of chromatographic technologies 
with higher separation capacity. Because of their 
considerable importance in human health care a high 
number of synthetic and natural compounds were 
investigated for possible anticancer activity. The different 
character of synthetic and natural products made necessary 
the separated discussion of the chromatographic techniques 
apployed for the investigation.  
Chromatographic investigation of synthetic 
anticancer drugs 
Liquid chromatography (LC) of synthetic anticancer 
drugs: Because of their high separation capacity various 
liquid chromatographic (LC) methods such as normal and 
reversed phase performance liquid chromatography (RP-
HPLC), ultra performance liquid chromatography (UPLC), 
size exclusion chromatography (SEC), gel permeation 
chromatography (GPC) have been frequently employed for 
the analysis of synthetic anticancer drugs and for their 
formulation. The oxidative damage to guanine nucleosides 
following combination chemotherapy with 5-fluorouracil 
and oxiplatin has been recently investigated using UPLC. It 
was established that chemotherapy increases the 
concentration of metabolites. It was further established, that 
smoking, sex, and age exerts a marked influence on the 
oxidative damage.1  
The analytical methods used for the determination of 
metallodrugs in biological samples have been recently 
collected and critically evaluated. Future trends have also 
been discussed in detail.2 The stability of 5-fluorouracil a 
widely used chemotherapeutic agent has been investigated 
under various conditions using HPLC and infrared 
spectroscopy (IR). HPLC measurements were carried out on 
a C18 reversed phase column the mobile phase consisted of 
40 mM KH2PO4. Analyted were detected at 260 nm. The 
relationship between the detector response and the 
concentration of the analyte was linear between 20  and 550 
µg mL-1. The coefficient of correlation was 0.9995. The 
relative RSD values of intra-day and inter-day were >0.2% 
and >1%. Investigations indicated that the decomposition 
rate of the analyte was higher in alkaline then in acidic 
conditions. UV radiation exerts a minimal influence on the 
stability of the drug.3 The effect of adryamycin treatment on 
the mouse splenic protein levels was studied in detail using 
reversed-phase liquid-chromatography-tandem mass 
spectrometry. The measurements indicated that the drug 
exerts a marked effect of the protein levels.4 The application 
of thermochemotherapy mediated by a new solar planet-
structured magnetic nanocomposites has been recently 
reported. Docetaxel (an anticancer drug) was encapsulated 
and the efficacy of encapsulation and the drug release was 
followed by HPLC. It was stated that the method can be 
employed as an effective mediator for magnetic 
thermochemotherapy.5 A new, specific and sensitive LC-
MS/MS analytical method was developed for the 
simultaneous determination of eleven thiopurine nucleotides. 
Synthetic products such as eleven mono-, di- and 
triphosphates of thioguanosine, methylthioinosine,  
methylthioinosine, thioinosine, and methylthioguanosine. It 
was further established that the RSD value was below 8%,  
the recovery varied between 92% and 107%. It was further 
found that the method can be successfully employed for the 
better understanding of thiopurine metabolism.6  
The behaviour of the anticancer drug doxorubicin (DOX) 
and it loaded form with poly(alkylcyanoacrylate) 
nanoparticles was studied by using HPLC technology. The 
method made possible the extraction of Dox and its 
metabolites by liquid-liquid extraction. The efficacy of 
extraction of total Dox (free Dox and Dox associated with 
nanoparticles) was 71 and 78 %. It was concluded from the 
data, that the within-day and between day precisions of the 
method were 97.1 – 102.9%  and 97.3 – 101.7%. It was 
further suggested that the method is suitable for the 
determination the pharmakokinetic and biodistribution of 
DOX associated with nanopaticles.7 Both SEC and HPLC 
were employed for the development and characterization of 
a niosomal formulation of doxorubicin aimed at brain 
targeting. Loaded and unloaded niosomes were separated by 
SEC. It was stated that niosomal formulations improve 
doxorubicin brain delivery.8 Doxorubicin-loaded Fe3O4 
magnetic nanoparticles were prepared and modified with 
biocompatible copolymers. The anticancer drug doxorubicin 
hydrochloride was encapsulated into poly (D,L-lactic co-
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glycolic acid) poly(ethylene glycol) (PLGA-PEG). The 
copolymers were characterized with 1H NMR spectroscopy, 
gel permeation chromatography, Fourier transform infrared 
spectroscopy, differential scanning calorimetry, X-ray 
powder diffraction, scanning electron microscopy and 
vibrating sample magnetometry. The drug encapsulation 
efficacy were 69.5%, 73% and 78% for PLGA, PEG(2000), 
PLGA, PED(3000) and PLGY PEG(4000), respectively. It 
was proposed that these nanoparticles can be employed for 
biomedical investigations.9 A LC/MS/MS method was 
developed and successfully applied for the determination of 
doxorubicin and its primary metabolite (doxorubicinol) in 
cultured human leukemia cells. Solid phase extraction was 
employed for the clean up and enrichment of analytes. The 
calibration range was 5.00-1000 mg mL-1 and 0.50-50 ng 
mL-1 for doxorubicin and its metabolite, respectively. It was 
established that the anticancer drug and its primary 
metabolite can be simultaneously determined by 
LC/MS/MS.1 
A new type of alendronate conjugated amphiphilic 
hyperbranched polymer based on Boltom H-40 and 
poly(ethylene glycol) for bone targeted drug delivery was 
synthesized. The star copolymer was investigated by FTIR 
and GPC. The investigations indicated that this type of 
micelles are highly promising bone-targeted drug carriers 
for skeletal metastases.11 Dendron-like poly(-
benzyloxycarbonyl-L-lysine)/linear PEO block copolymers 
were synthesized and their behaviour under various 
conditions was investigated. The physicochemical 
characteristics were investigated by FTIR, 1H-NMR, GPC, 
differential scanning calorimetry, polarized, optical 
microscopy, and wide range X-ray.12  
A new type of cyclodextrin-overhanging hyperbranched 
core-couble-shell miktoarm architectures were developed. 
The polymers were characterized by 1H-NMR, FTIR, 
SEC.13 Affinity chromatography was employed for the 
determination of the effect of spectrin  II and  II tetramers 
on the platinum anticancer drug resistance in ovarian serous 
adenocarcinoma. The measurements indicated that proteins 
Spectrin  II and  II may contribute to drug resistance.14 
The effect of sodium thiosulphate on the metabolism of 
cisplatin in human plasma has been investigated by using 
size exclusion chromatography coupled to an inductively 
coupled plasma atomic emission spectrometer. It was 
established that the results can be used to develop feasible 
strategies to reduce the side effects of Pt-based anticancer 
drugs in patients.15  
Biocompatible amphiphilic block copolymers with various 
molecular weight were synthesized and applied for the 
development of anticancer drug nanocarriers. The new 
copolymers were characterized by nuclear magnetic 
resonance and gel permeation chromatography. It was 
established that the new copolymers can be employed for 
the development of drug delivery systems with various 
molecular weight and with drug various drug loading 
capacity.16 The anticancer drug methotrexate (MTX) was 
incorporated in layered ceramic nanoparticles of layered 
double hydroxides (LDHs). The nanoassemblies showed 
marked elevated chemical and thermal stability as 
detemined with HPLC measurements. It was assumed that 
the high cellular uptake may be due to the enhanced drug 
efficacy.17 Pharmacokinetics of the peptide mediated 
delivery on the anticancer drug ellipticine has been  
investigated in detail. The complex of the amino acid 
pairing peptide (EAK16II) with the hydrophobic anticancer 
agent ellipticine was prepared and the pharmacokinetics 
parameters were determined by HPLC. The measurements 
indicated that EAK prolongs the residence time of the drug 
and increases the bioavailability.18 The synthesis and 
characterization of poly(ethylene glycol)-b-poly(epsilon-
caprolactone) copolymers with functional side groups on the 
polyester block was reported. The new polymers were 
characterized with differential scanning calorimetry, 1H 
NMR, GPC, fluorescence spectroscopy, transmission 
electron microscopy, and dynamic light scattering. The 
weak drug entrapment efficacy and drug-loading ability of 
these copolymers were established.19  
The oral bioavailability and gender-related 
pharmacokinetics of celastrol, an anti-inflammatory and 
antitumor agent was investigated by LC/MS/MS. The 
measurements indicated that the LC/MS/MS method was 
selective, and precise. It was further found that formulation 
markedly increased the bioavailability, and female rats 
showed significantly better absorption then males.20 Surface 
modification of paclitaxel-loaded polymeric nanoparticles 
was achieved and the in vitro cellular behaviour and in vivo 
pharmacokinetics was studied in detail. Samples were 
analysed with atomic force microscopy, dynamic light 
scattering, and cell confocal microscopy. It was concluded 
from the results that the surface modification of polymeric 
nanoparticles results in modified pharmacokinetik 
behavior.21  
LC/MS/MS technology was employed for the 
simultaneous determination of seven commonly used 
anticancer drugs. The anticancer agents included in the 
investigations were: cyclophosphamide, ifosfamide, 
irinotecan, eloposide, gemcitabine, carboplatin and 
permetrexet. The separation of analytes was carried out on a 
C18 column (2.1 mm x 100 mm), 3 mm particle size. 
Positive electrospray ionization was employed as the 
ionization source. Mobile phase consisted of acetone-water 
(0.1%  formic acid and 10 mM ammonium acetate). The 
flow rate ranged 0.1 – 0.25 mL min-1. Linear coefficients 
were  always over 0.992. The recovery ranged from 50 to 
81.0%. The method was successfully applied to samples 
from cancer patients.22 An LC-MS method and radiometric 
detection was developed for the study of the disposition, 
metabolism, and excretion of the orally active 
pandeacetylase inhibitor in cancer patients. Recovery of 
radioactivity in excreta was 87% (44 – 77%  in feces and 
29–51% in urine). Approximately 40 metabolites were 
detected, in was found that biotransformation begins at the 
hydroxamic acid side chain and ethyl-methyl indole moiety. 
It was further established that panobinostat and metabolites 
are excreted by both kidney and liver.23  
Liquid chromatography combined with electrospray 
ionization mass spectrometry was employed for the 
investigation of chronic doxorubin cardiotoxicity in rats. 
The measurements indicated that doxorubicin influences the 
cardiac cytochrom P450-mediated arachidonic acid 
metabolism.24  
Ultra performance liquid chromatography (UPLC) 
followed with electrospray ionization quadrupole time of 
flight mass spectrometry was applied for the investigation of 
the metabolites of the antitumor drug noscapine. The 
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method detected some new primary phase metabolites such 
as an N-demethylathed product, two hydroxylated 
derivatives, one bis-demethylated derivative. Several novel 
glucuronides have also been detected.25 A high performance 
liquid chromatographic method coupled with electrospray 
mass spectrometry (LC-ESMS) was developed for the 
investigation of the structural and functional diversity in 
DNA-targeted  hybrid anticancer drugs. It was stated that 
the new method can be successfully employed for the 
detemination of structure-activity relationships and for the 
identification of target compounds.26  
The structure of the new anticancer agent EAPB0203 and 
its metabolites were investigated in detail. Measurements 
were carried out using liquid chromatography-mass 
spectrometry and LC/MS/MS. The structures of the 
metabolites were identified by one and two dimensional H-
NMR.27 A new immunoassay method was developed for the 
determination of 5-fluorouracil (5-FU) in patients with 
gastric cancer. The results were compared with those 
obtained with the application of GC-MS. It was established 
that the results of the immunoassay method and GC/MS 
were comparable and can be employed simultaneously for 
the determination of 5-FU in the plasma of patients with 
gastric cancer. It was further established that the 
immunossay method is simpler and easier to carried out than 
the traditional GC/MS procedure.28  
Chiral chromatography combined with other 
physicochemical analytical procedures has been successfully 
applied for the investigation of the chemistry and 
pharmacology of Imexon and related cyanoaziridines. The 
measurements indicated that the activity of these new 
compounds was relatively low compared with the activity of 
the original compounds.29  
The interaction between of RAPTA-T, a new ruthenium-
based anticancer agent and human ovarian cells was 
investigated in detail. SEC has been employed for the 
determination of the distribution profile of metallodrug 
within the cancer cells. Multidimensional protein 
identification technology was employed for the elucidation 
of the cellular response mechanism. It was established that 
the investigation methods employed may help the 
elucidation of the interaction between the cancer cells and 
the anticancer drug.30 A combining data acquisition method 
followed with multi-period ion scan and high resolution 
characteristics extracted ion chromatograms were employed 
for in-vivo drug metabolites screening and identification of 
the metabolites of the potential antitumor agent 3,6,7-
trimethyloxyphenantroindolizine (CAT) in rat urine. It was 
established that the method is suitable for the detection of 21 
metabolites and for the identification or 9 metabolites in rat 
urine. Furthermore the method allowed the differentiation 
between N-oxidized and hydroxylated metabolites.31 A new 
type of folic acid conjugated amphiphilic 4-arm star-shaped  
PLGA-PEG-NH2 were synthesized and tested as nanocarrier 
for doxorubicin. The characteristics of the preparation were 
assessed by H-1 NMR, dynamic light scattering and GPC. It 
was established that the new nanocarrier can be successfully 
applied for the deliver of doxorubicine.32 The composition 
of the ethanolic extract of the chemopreventive Taiwanese 
mushroom Antrodia camphorata was investigated by HPLC. 
The measurements indicated that the triterpenoid rich 
fraction contained antileukemia components such as anticin, 
dehydroeburicoic acid, and zhankuic acid. It was found that 
the bioactive components decrease tumor weight and size 
without decreasing body weight. The preparation was 
proposed for the treatment of leukaemia.33  
Capillary elctrophoresis (CE) combined with laser-
induced fluoescence detection (LIF) has been employed for 
the study of the interaction of the antitumor agent ellipticine 
with DNA. The background electrolyte contained 20% 
dimethyl sulfoxide and 50 mM sodium acetate (pH 4.5). It 
was established that the peak of ellipticine decreased in the 
presence of DNA indicating the interaction of ellipticine 
with DNA.34  
A HPLC/MS method was developed for the determination 
of CM1, the active agent derived from the prodrug CA1P, in 
human plasma and urine, and of CAIP and three 
glucuronides CA1G1, CA1G2, and CA1DG in human urine 
were analysed. Plasma CA1was preconcentrated by solid 
phase extraction (SPE). Urine samples were investigated 
without extraction. The intra-day and inter-day accuracy and 
precision were lower then 15%. Mean recovery of CA1 
from plasma was 101% and 97% from urine. Mean urine 
recovery was of CA1P was 98%, CA1G1 96%, CA1G2 93% 
and CM1DG 93%.35 A new GnRH-based multifunctional 
drug delivery system containing daunorubicin and 
methotrexate was developed and the in vitro stability, 
degradation in human serum, and in the presence of rat liver 
homogenate was investigated by LC/MS. It was concluded 
from the results that multifunctional bioconjugate resulted in 
higher in vitro cytostatic effect than the monofunctional 
bioconjugate contain either methotrexate or daunorubicin.36  
Fluorinated, and pegylated polyaspartamide copolymers 
were synthesized to increase the solubility and efficacy of 
flutamide. The characteristics of copolymers were 
determined by SEC, pyrene colorimetric assay, light 
scattering analysis and scanning electron microscopy. The 
results indicated that the inclusion of flutamide in polymer 
matrices markedly modifyes the efficacy of the complexed 
bioactive compound.37 The characteristics of the newly 
synthesized anticancer agent, 7-(4-fluorobenzylamino)-1,3,-
4,8-tetrahydropyrrolo[4,3,2-d,e]quinolin-8(1H)-one (FBA-
TPQ) were investigated employing various physicochemical 
and biophysical investigation methods such as rapid 
resolution liquid chromatography, determination of FBA-
TPQ in plasma and tissue samples, stability in plasma, 
plasma protein binding, metabolism by S9 enzymes, plasma 
pharmacokinetics, and tissue  distribution. It was concluded 
from the data that FBA-TPQ is a potential therapeutic agent 
for pancreatic cancer.38  
The pharmakokinetics and antitumor activity of XMT-
1001, a new polymeric topoisomerase I inhibitor was 
investigated in mice bearing HT-29 human colon carcinoma 
xenografts. LS/MS method was employed for the 
determination of the chromatographic profile of the drug 
and its conjugate release products. It was established that the 
efficacy of drug was markedly modifyed by formulation.39  
An LC-MS/MS technology was developed and applied for 
the simultaneous determination of highly hydrophobic 
pyrimidine anticancer agents in human plasma and the 
efficacy of three derivatization reagents were compared. The 
anticancer agents included in the experiments were tegafur, 
5-fluorouracil and gimeracil. Derivatization agents 
employed were p-bromophenacyl bromide, dansyl chloride 
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and diazomethane. The experiments revealed that the p-
bromophenacyl was the best derivatization agent. The 
method was employed for the pharmakinetic study of 
tegafur, 5-fluorouracil and gimeracil in cancer patients.40 
The purification and characterization of lunasin, a peptide 
isolated from soy bean has been recently reported. The 
interest in lunasin is due to its marked anticancer and anti 
inflammatory actvity. A combined method was developed 
for the purification of lunasin from soybean. The method 
includes anion exchange chromatography, ultrafiltration and 
reversed-phase chromatography. It was stated that the 
procedure facilitates the development of lunasin as a 
potentional nutraceutical of therapeautic anticancer agent.41  
The safety and pharmacokinetics of -tocopheryloxy 
acetic acid (-TEA) was investigated using LC/MS 
technologies. The measurements were motivated by the 
antitumor activity of -TEA. According to the results -
TEA showed no toxic effect, the half life of orally 
administered alpha-TEA was 52 h. No clinical signs of 
toxicity was detected. No significant sex specific differences 
were established.42 
A novel LC-MS/MS procedure was developed for the 
quantification of E7080 (lenvatinib) and metabolites in 
various human biological matrices such as human plasma, 
whole blood, urine and faeces. Plasma, urine, and faeces 
samples were extracted with acetonitrile. Analyses were 
carried out on an octadecyl-silica column (50 mm x 2.1 mm). 
Analytes were separated using gradient elution consisting of 
water-acetonitrile mixtures and detected with API300 triple 
quadrupole mass spectrometer with turbo ion spray interface 
operating in positive ion mode. Cailbration curves were in 
each case linear, accuracy varied between ±20%. It was 
found that the method can be successfully employed for the 
analysis of E7080 and its metabolites in various human 
biological matrices.43  
A liquid chromatography-tandem mass spectrometry (LC-
MS/MS) analytical procedure was applied for the separation 
and quantitative determination of felotaxel (SHR110008) in 
tumor-bearing mice. Samples (plasma, urine, faeces, brain 
heart, liver, lung ) were extracted with ethyl acetate. 
Calibration curves were linear (r2=0.995). The accuracy and 
precision varied between 86.1–107.2 % and 1.1-9.2%. 
Recoveries ranged from 73.9 to 96.1 %.44  
A HPLC method was employed for the analysis of 
doxorubicin (Dox) loaded poly(alkyl cyanoacrylate, PACA) 
nanoparticles. The measurements indicated that Dox and its 
main metabolites doxorubicinol and doxorubicinon are well 
separated from the target compound. It was further 
established that recovery varied between 71 and 78%. The 
between –day and within-day precision of the method varied 
from 97.1 to 102.9% and from 97.3 to 1.02 %.45 Another 
LC-MS method was developed for the investigation of 
pharmacokinetics of  the anticancer drug CYC-116 in rat 
plasma. Analytes were separated on an octadecysilica 
column (150 x 04.6 mm, particle size, 5 µm) using isocratic 
separation mode. The flow rate was 0.8 mL min-1. Isocratic 
mobile phase consisted of acetonitrile-water-formic acid: 
23.5; 76.5; 0.1 v/v/v). Analytes were extracted by liquid-
liquid extraction using ethyl acetate. MS analysis was 
carried out employing a quadruple mass spectrometer. The 
calibration curve was linear in the concentration range 
investigated. The intra- and interday precisions were less 
then 11.8–6.6 %. It was stated that the method can be 
successfully applied for the study of the pharmacokinetik of 
CYC-116 in rats after oral administration.46  
A LC/MS/MS procedure was developed for the 
simultaneous determination of eleven thiopurine nucleotides 
(mono-, di- and triphosphates of thioguanosine, 
methylthioinosine, methylthioguanosine, and thioinosine). 
Target compounds show marked anticancer and 
immunosuppressive activity. It was established that  the 
method facilitate the understanding of the thiopurine 
metabolism in one run.47  
The application of thermochemotherapy mediated by 
novel solar-planet structured magnetic nanocomposite for 
glioma treatment has been reported. The efficacy of the 
encapsulation of docetaxel and drug release was followed by 
HPLC. It was concluded from the results that this novel 
method can be successfully employed for the comprehensive 
treatment of glioma.48  
The stability of 5-fluorouracyl under different 
environmental conditions was investigated by using HPLC 
and infrared spectroscopy (IR). Analytes were separated on 
an octadecylsilica column using 40 mM KH2PO4 as mobile 
phase. Target compounds were detected at 260 nm. 
Significant linear correlation was found between the 
concentration of detector response and the amount of 
analytes in the samples (r2=0.9995). The R. S. D. values for 
intra-day and inter-day were <0.2% and <1%, respectively. 
The measurements indicated that the analyte is sensitive to 
oxidative conditions and stable when exposed to UV 
irradiation.49  
Another LC-MS/MS technique was developed and 
successfully employed for the simultaneous determination 
of doxorubicin and its metabolite in cultured human 
leukemia cells. Samples were enriched using solid phase 
extraction, the validated calibration ranges were 5.00 – 1000 
mg mL-1. The data indicated that the method is precise and 
can be applied for the simultaneous determination of the 
drug and its metabolite.50  
Niosomal formulations were developed, characterized and 
applied as potential brain targeted system. Light scattering 
and transmission electron microscopy were applied for the 
characterization of vesicles. SEC or dialysis was applied for 
the investigation of the physicochemical parameters of 
vesicles. It was concluded from the results that the method 
in suitable to improve the doxorubicin brain delivery.51 A 
novel  (NAG)-PEG-doxorubicin targeted conjugates were 
designed, developed, synthesized for its capacity as 
anticancer delivery agent. The product was characterized by 
1H.NMR, UV spectroscopy and HPLC. It was concluded 
from the results that the new products can be applied in 
targeted anticancer therapy.52 The in vivo performance and 
in vitro cytotoxicity of 10-hydroxycamptothecin (10-HCPT) 
was investigated in detail. The effect of 10-HCPT 
nanosuspernion and 10-HCPT solution was compared and 
critically evaluated. HPLC-FD was employed for the 
analysis of serum samples and tissue homogenizates. It was 
further found that 10-HCPT increases the cytotoxycity of 
the original anticancer agent. Increase the anti-tumor 
activity of poorly soluble bioactive compound.53 The 
solubility of paclitaxel (PTX) was improved by using 
various coprecipitation processess including poly (L-lactic 
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acid, PLLA). The components of the formulation were 
mixed and coprecipitated by a supercritical antisolvent 
(SAS) process using dichloromethane (DCM) and mixtures 
of DCM and ethanol, or DCM and dimethyl sulfoxide 
(DMSO). The end product was characterized by X-ray 
diffraction (XRD), scanning electron microscopy (SEM), 
laser diffraction, particle size analysis, and HPLC. The 
experimental conditions for the optimal system were: 
DCM/EtOH 50:50 %, 35 0C, 10-12 MPa, PLLA 
concentration, 5 g L-1; solution flow rate 0.5 ml min-1.54  
The anticancer applications of mesoporous materials 
functionalized with the natural betulinic acid (BA) has been 
investigated in detail. Dehydrated CMC-41 was 
functionalized with 3-chloropropyltriethoxysilane (CPTS) 
and 3-aminopropyltriethoxysilane (APTS). The end product 
was characterized by powder X-ray diffraction, X-ray 
fluorescence, nitrogen gas sorption, multinuclear MAS 
NMR spectroscopy, thermogravimetry, UV spectroscopy, 
IR, SEM, and HPLC.55  
The characteristic of methoxy stilbenes as potent, specific, 
untransported and cytotoxic inhibitory of breast cancer 
resistance protein has been studied in detail. It was 
established by HPLC and mass spectrometry titration that 
methoxystilbenes are not transported. It was further 
suggested that the methoxy derivatives of stilbene can be 
applied to influence drug-efflux activity.56 The light-
mediated release of the anticancer drug methotrexate was 
investigated employing three different analytical methods 
such as UV/vis spectrometry, 1H NMR spectroscopy and 
HPLC. The measurements indicated that the drug is released 
by the photochemical mechanism in an actively controled 
manner. It was further found that the release of methotrexate 
depended on the linker design, light wavelenght, exposure 
time, and the pH of the medium.57  
An octadecyl-silica column was applied for the separation 
and quantitative determination of some new benzimidazole 
derivatives with marked cytotoxic activity. The stability of 
the target compounds was investigated in aqueous solution 
of 0.2% dimethyl sulfoxide. The mobile phase of the HPLC 
measurements consisted of acetate buffer (pH 
4.5):acetonitrile. The flow rate was 1.0 mL min-1. The 
correlation coefficients were over r2 = 0.9995. The new 
method was proposed for the HPLC analysis and stability 
test of these novel benzimidazole derivatives.58  
During the study of the pharmacokinetics of the amino-
pairing peptide EAK16-II (EAK) it was established that 
EAK is suitable for the stabilization of EAK-EPT 
(ellipticine) complexes in vivo. The characteristics of the 
EAK-EPT complexes were investigated by transmission 
electron microscopy TEM), HPLC and zero potential 
measurements. EPT was extracted from rat plasma with 
dexamethasone sodium phosphate. The measurements found 
significant differences between EPT and EAK-EPT 
complexes indicating that EAK can be applied as a carrier to 
increase the biovailability of EPT.59  
The design and synthesis of photoactivatable metallodrugs 
has been recently published. The compounds included in the 
experiments were: inert (Ru(II) half sandwich compounds, 
[Ru([9]aneS(3)(bpy)(py)][PF6] ([9]aneS(3)=1,4,7-trithia-
cyclononane, bpy=2,2’-bipyridine, py=pyridine), 
[Ru([9]aneS(3))(en)(py)][PF6] (en=1,2-diaminoethane), and 
[Ru([9]aneN(3))(en)(dmso-S)][PF6], [9]aneN(3)=1,4,7-
triazacyclononane), is reported along with the X-ray crystal 
structure of [Ru([9]aneS(3)(bpy)(py)][PF6]. It was 
established that these complexes are promising for further 
investigation as potential photochemotheropeutic agents.60  
A new potential PET (positron emissin tomography) agent 
was synthesized for imaging steroid sulfatase (STS) in 
cancers. Solid phase extraction combined with HPLC was 
employed for the purification the target tracer.61 The murine 
pharmakokinetics, pharmacodynamics and metabolism of 
(3-(1H-indol-2-yl-phenyl)(1H-indol-2yl-methanone) (in-
dole-15). The concentration of indole-15 was determined by 
HPLC and LC/MS/MS. The investigation of metabolites 
indicated that the original compound undergoes extensive 
oxidative metabolism with following surfation. It has been 
proposed that indole-15 can be employed in clinical trials.62 
A specific and sensitive enzyme-linked immunosorbent 
assay (ELISA) was developed for the analysis of Vindesine 
(VDS) and the results were compared with those obtained 
by HPLC. Anti-VDS antibody was obtained by immunizing 
rabits with  VDS conjugated  with bovine serum albumin 
using N-[-4-(diazophenyl)ethyl]maleinimide. The enzyme 
marker was produced by coupling VDS with horse radish 
peroxidase using N-4-diazophenylmaleinimide. The method 
was highly specific the cross reactivity was 0.18% for 
vincristine and 0.11 % for vinblastine. It has been stated that 
the method can be successfully employed for the 
pharmacokinetics studies of (VDS).63 The mass balance, 
excretion and metabolism of the small molecule  flavonoid 
tumour vascular disrupting agent ASA404 was investigated 
using various chemical, physicochemical methods such as 
HPLC, liquid scintillation counting, mass spectrometry, 
glusulase. The mean recoveries were: urine, 59.9%; faeces, 
33.3%. It was found that the method is suitable for the 
detection and analysis of two new metabolites did not 
detected before.64  
A new HPLC method was developed for the study of new 
anticancer agents in intravenous solutions. Compounds 
included in the exteriments were the derivatives of 
daunorubicin containing various amidine group such as 
piperidine (DD-1), morpholine (DD-2, pyrrolidine (DD-3), 
or hexahydroazepine (DD-4) moiety. It was found that the 
environmental conditions exert marked effect on  the 
stability of the preparation.65 A TAT peptide fragment 
(YGRKKRQRRR) was conjugated to a platinum(IV) 
analogue of oxiplatin as a vehicle for membrane penetration. 
The mono- and difunctionalized conjugates were separated 
by preparative HPLC and characterized by analytical HPLC, 
ESI-MS, and H-1 NMR spectroscopy. The results indicated 
that the biological activity of conjugates was higher then 
that of the untargeted analogues.66 The influence of of 
miRNAS a regulator in some biological processes such as 
development, cellular differentiation, and carcinogenesis 
was investigated in detail. The promising anticancer drug 
3,6-dihydroxyflavone (3,6-DHF) was selected as model 
compound. HPLC was employed for the detection of the 
bioavailability of 3,6-DHF. Cell apoptosis was determined 
by flow cytometry or terminal deoxynucleotidyl transferase 
UTP nick end-labeling assay. The investigations indicated 
that the oral administration of 3,6-DHF suppressed the 
breast carcinogenesis inducated by 1-methyl-1-nitrosourea 
(MNU) in rats. It was further found that 3,6-DHF is a potent 
natural chemopreventive agent, and miR-34a and miR-21 
play a considerable role in MNU-induced breast 
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carcinogenesis.67 Long conjugated 2-nitrobenzyl-derivative 
caged anticancer prodrug with visible light regulated release 
was synthesized. Styryl conjugated 2-nitrobenzyl derivatives 
were introduced in the molecules as phototrigger to regulate 
the release of the anticancer drug chrorambucil. UV 
absorption, FT-IR and HPLC technologies were applied for 
the study of the regulated release of the parent molecule.68 
The efficacy of a non-hypercalcemic vitamin-D-2 derived 
anti cancer agent (MT19c) was investigated. The 
investigation indicated that the new compound makes 
possible of the future potential application of this 
compounds as anticarcinogen agent.69  
Reversed phase thin layer chromatography has also found 
applications in the chromatographic analysis of bioactive 
compounds. Stationary phases consisted of octadecyl silica  
and silica surface modified with cyano groups. Methanol-
water and acetonitrile-water mixtures served as stationary 
phases. Significant correlations were found between the 
lipophilicity determined with RP-TLC and calculated with 
principal component analysis. The chromatographic 
parameters of bioactive compounds included in the 
experiment were correlated with the biological activity of 
the analytes (quantitative structure-retention relationship and 
quantitative structure-activity relatiohship). The 
measurements indicated that the there is a significan 
correlation between the lipophilicity and molecular 
descriptors of phytol derivatives. It was assumed that the 
chromatographic behaviour of phytol derivatives may 
influence their penetration and partitioning over 
biomembranes.70  
Abbreviations 
APTS   3-aminopropyltriethoxysilane 
CA   Capillary electrophoresis 
CPTS 3-chloropropyltriethoxysilane 
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DMSO  dimethyl sulfoxide 
FTIR  Fourier transformed infrared spectroscopy 
GPC  gel permeation chromatography 
HPLC  high performance liquid chromatography 
MNU  1-methly-1-nitrosourea 
IR  infrared spectroscopy 
PET  positron emision tomography 
PLLA  poly-L-lactic acid 
PTX  paclitaxel 
LIF  Laser-induced fluorescence detection 
RP-HPLC LC-MS/MS reversed-phase high performance  
liquid chromatography-tandem mass spectro-
metry 
RSD  relative standard deviation 
SEM  scanning electron microscopy 
SEC  size exclusion chromatography 
SPE  solid phase extraction 
UPLC  ultra performance liquid chromatography 
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